Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

krka uk ltd - tapentadol - modified-release tablet - 150mg

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - tapentadol - modified-release tablet - 150mg

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - tapentadol - modified-release tablet - 150mg

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - tapentadol - modified-release tablet - 250mg

Canada - Tiếng Anh - Health Canada

janssen inc - tapentadol (tapentadol hydrochloride) - tablet (extended-release) - 50mg - tapentadol (tapentadol hydrochloride) 50mg - opiate agonists

Canada - Tiếng Anh - Health Canada

janssen inc - tapentadol (tapentadol hydrochloride) - tablet (extended-release) - 150mg - tapentadol (tapentadol hydrochloride) 150mg - opiate agonists

Canada - Tiếng Anh - Health Canada

janssen inc - tapentadol (tapentadol hydrochloride) - tablet (extended-release) - 250mg - tapentadol (tapentadol hydrochloride) 250mg - opiate agonists

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 100 mg - like other drugs with mu-opioid agonist activity, nucynta® is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta® is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . like drugs with mu-opioid agonist activity, nucynta® is contraindicated in any patient who has or is suspected of having paralytic ileus. nucynta® is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events [see drug interactions (7.4)] . pregnancy category c. tapentadol hcl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous and subcutaneous exposure during the period of embryofetal organogenesis. w

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

physicians total care, inc. - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol hydrochloride 50 mg - nucynta® (tapentadol) is indicated for the relief of moderate to severe acute pain in patients 18 years of age or older. enter section text here like other drugs with mu-opioid agonist activity, nucynta® is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta® is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . like drugs with mu-opioid agonist activity, nucynta® is contraindicated in any patient who has or is suspected of having paralytic ileus. nucynta® is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events [see drug interactions (7.4)] . enter section text here pregnancy category c

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

stat rx usa llc - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol hydrochloride 75 mg - like other drugs with mu-opioid agonist activity, nucynta® is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta® is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . like drugs with mu-opioid agonist activity, nucynta® is contraindicated in any patient who has or is suspected of having paralytic ileus. nucynta® is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events [see drug interactions (7.4)] . pregnancy category c. tapentadol hcl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous and subcutaneous exposure during the period of embryofetal organogenesis. w